Ovarian clear cell carcinoma (OCCC) is one of the rare subtypes of ovarian cancer, yet its
prognosis is extremely poor. Previous studies indicates that both bevacizumab and PD-1
inhibitor have clinical benefit for OCCC patients. And the combination of bevacizumab and
PD-1 inhibitor has shown preliminary safety and clinical activity. Therefore, this study aims
to investigate the protential benefit of combation therapy for patients with OCCC.
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.